6.
Iscovich J, Abdulrazik M, Cour C, Fischbein A, Peer J, Goldgar D
. Prevalence of the BRCA2 6174 del T mutation in Israeli uveal melanoma patients. Int J Cancer. 2002; 98(1):42-4.
DOI: 10.1002/ijc.10155.
View
7.
Cunniff C, Bassetti J, Ellis N
. Bloom's Syndrome: Clinical Spectrum, Molecular Pathogenesis, and Cancer Predisposition. Mol Syndromol. 2017; 8(1):4-23.
PMC: 5260600.
DOI: 10.1159/000452082.
View
8.
Saint-Ghislain M, Derrien A, Geoffrois L, Gastaud L, Lesimple T, Negrier S
. MBD4 deficiency is predictive of response to immune checkpoint inhibitors in metastatic uveal melanoma patients. Eur J Cancer. 2022; 173:105-112.
DOI: 10.1016/j.ejca.2022.06.033.
View
9.
Hearle N, Damato B, Humphreys J, Wixey J, Green H, Stone J
. Contribution of germline mutations in BRCA2, P16(INK4A), P14(ARF) and P15 to uveal melanoma. Invest Ophthalmol Vis Sci. 2003; 44(2):458-62.
DOI: 10.1167/iovs.02-0026.
View
10.
Virgili G, Gatta G, Ciccolallo L, Capocaccia R, Biggeri A, Crocetti E
. Incidence of uveal melanoma in Europe. Ophthalmology. 2007; 114(12):2309-15.
DOI: 10.1016/j.ophtha.2007.01.032.
View
11.
Van Raamsdonk C, Griewank K, Crosby M, Garrido M, Vemula S, Wiesner T
. Mutations in GNA11 in uveal melanoma. N Engl J Med. 2010; 363(23):2191-9.
PMC: 3107972.
DOI: 10.1056/NEJMoa1000584.
View
12.
Abdel-Rahman M, Pilarski R, Ezzat S, Sexton J, Davidorf F
. Cancer family history characterization in an unselected cohort of 121 patients with uveal melanoma. Fam Cancer. 2010; 9(3):431-8.
DOI: 10.1007/s10689-010-9328-7.
View
13.
Johansson P, Stark A, Palmer J, Bigby K, Brooks K, Rolfe O
. Prolonged stable disease in a uveal melanoma patient with germline MBD4 nonsense mutation treated with pembrolizumab and ipilimumab. Immunogenetics. 2019; 71(5-6):433-436.
DOI: 10.1007/s00251-019-01108-x.
View
14.
Sondka Z, Bamford S, Cole C, Ward S, Dunham I, Forbes S
. The COSMIC Cancer Gene Census: describing genetic dysfunction across all human cancers. Nat Rev Cancer. 2018; 18(11):696-705.
PMC: 6450507.
DOI: 10.1038/s41568-018-0060-1.
View
15.
Dompmartin A, van der Vleuten C, Dekeuleneer V, Duprez T, Revencu N, Desir J
. GNA11-mutated Sturge-Weber syndrome has distinct neurological and dermatological features. Eur J Neurol. 2022; 29(10):3061-3070.
DOI: 10.1111/ene.15452.
View
16.
Rodrigues M, Mobuchon L, Houy A, Alsafadi S, Baulande S, Mariani O
. Evolutionary Routes in Metastatic Uveal Melanomas Depend on Alterations. Clin Cancer Res. 2019; 25(18):5513-5524.
DOI: 10.1158/1078-0432.CCR-19-1215.
View
17.
Lobo J, Pinto C, Freitas M, Pinheiro M, Vizcaino R, Oliva E
. Ovarian metastasis from uveal melanoma with MLH1/PMS2 protein loss in a patient with germline MLH1 mutated Lynch syndrome: consequence or coincidence?. Virchows Arch. 2016; 470(3):347-352.
DOI: 10.1007/s00428-016-2052-4.
View
18.
Rai K, Pilarski R, Boru G, Rehman M, Saqr A, Massengill J
. Germline BAP1 alterations in familial uveal melanoma. Genes Chromosomes Cancer. 2016; 56(2):168-174.
PMC: 5490375.
DOI: 10.1002/gcc.22424.
View
19.
Palles C, West H, Chew E, Galavotti S, Flensburg C, Grolleman J
. Germline MBD4 deficiency causes a multi-tumor predisposition syndrome. Am J Hum Genet. 2022; 109(5):953-960.
PMC: 9118112.
DOI: 10.1016/j.ajhg.2022.03.018.
View
20.
Cuddapah V, Dubbs H, Adang L, Kugler S, McCormick E, Zolkipli-Cunningham Z
. Understanding the phenotypic spectrum of ASXL-related disease: Ten cases and a review of the literature. Am J Med Genet A. 2021; 185(6):1700-1711.
PMC: 8842511.
DOI: 10.1002/ajmg.a.62156.
View